Picks

Another Paragon spinout goes public through reverse merger

STAT+: BlackRock to buy majority stake in Humana’s CenterWell clinics for $2.8 billion

J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent

Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins

罗氏1亿美元首付获大睿生物ALK7肥胖症项目权益，总额最高11.6亿美元

Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

Envisagenics与勃林格殷格翰达成超10亿美元合作，开发RNA剪接精准疗法治疗实体瘤

OpenAI两大创始人押注的Aspen Neuroscience递交IPO申请，拟募资1亿美元推进帕金森病细胞疗法

GSK commits $800M to R&D, manufacturing hub, as Pennsylvania bonds deepen - Fierce Pharma

TRexBio 完成 IPO 募资约 7.81 亿元，礼来拟按发行价认购不超 19.9%

最新进展10月9日 22:13TRexBio、Retension完成IPO共融资1.617亿美元

Matchpoint’s $150M tops the week’s private rounds: Venture Report

赛诺菲守擂，诺华豪赌：百亿BD转向自免

Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset - Fierce Biotech

晖致 16.5 亿美元收购 Pacira 加码非阿片类疼痛业务

Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

Merck barred from making subcutaneous Keytruda in 8 European countries

艾伯维约109亿美元收购Apogee Therapeutics，获得IL-13单抗zumilokibart等后期管线

RougeTx: Reattaching pericytes to stabilize vessels in HHT

Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up